GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ACADIA Pharmaceuticals Inc (FRA:DR6) » Definitions » Cyclically Adjusted PB Ratio

ACADIA Pharmaceuticals (FRA:DR6) Cyclically Adjusted PB Ratio : 3.92 (As of May. 21, 2024)


View and export this data going back to 2004. Start your Free Trial

What is ACADIA Pharmaceuticals Cyclically Adjusted PB Ratio?

As of today (2024-05-21), ACADIA Pharmaceuticals's current share price is €13.48. ACADIA Pharmaceuticals's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 was €3.44. ACADIA Pharmaceuticals's Cyclically Adjusted PB Ratio for today is 3.92.

The historical rank and industry rank for ACADIA Pharmaceuticals's Cyclically Adjusted PB Ratio or its related term are showing as below:

FRA:DR6' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 3.86   Med: 13.23   Max: 27.83
Current: 3.94

During the past years, ACADIA Pharmaceuticals's highest Cyclically Adjusted PB Ratio was 27.83. The lowest was 3.86. And the median was 13.23.

FRA:DR6's Cyclically Adjusted PB Ratio is ranked worse than
72.84% of 648 companies
in the Biotechnology industry
Industry Median: 1.745 vs FRA:DR6: 3.94

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

ACADIA Pharmaceuticals's adjusted book value per share data for the three months ended in Mar. 2024 was €2.588. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is €3.44 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


ACADIA Pharmaceuticals Cyclically Adjusted PB Ratio Historical Data

The historical data trend for ACADIA Pharmaceuticals's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ACADIA Pharmaceuticals Cyclically Adjusted PB Ratio Chart

ACADIA Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 17.99 19.15 7.13 4.32 8.22

ACADIA Pharmaceuticals Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.99 6.30 5.45 8.22 4.83

Competitive Comparison of ACADIA Pharmaceuticals's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, ACADIA Pharmaceuticals's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ACADIA Pharmaceuticals's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ACADIA Pharmaceuticals's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where ACADIA Pharmaceuticals's Cyclically Adjusted PB Ratio falls into.



ACADIA Pharmaceuticals Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

ACADIA Pharmaceuticals's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=13.48/3.44
=3.92

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ACADIA Pharmaceuticals's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, ACADIA Pharmaceuticals's adjusted Book Value per Share data for the three months ended in Mar. 2024 was:

Adj_Book=Book Value per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=2.588/131.7762*131.7762
=2.588

Current CPI (Mar. 2024) = 131.7762.

ACADIA Pharmaceuticals Quarterly Data

Book Value per Share CPI Adj_Book
201406 2.595 100.560 3.401
201409 2.572 100.428 3.375
201412 2.509 99.070 3.337
201503 2.627 99.621 3.475
201506 2.268 100.684 2.968
201509 2.008 100.392 2.636
201512 1.799 99.792 2.376
201603 3.545 100.470 4.650
201606 3.200 101.688 4.147
201609 4.253 101.861 5.502
201612 4.049 101.863 5.238
201703 3.507 102.862 4.493
201706 3.020 103.349 3.851
201709 2.580 104.136 3.265
201712 2.277 104.011 2.885
201803 1.977 105.290 2.474
201806 1.813 106.317 2.247
201809 1.532 106.507 1.895
201812 2.927 105.998 3.639
201903 2.569 107.251 3.156
201906 2.383 108.070 2.906
201909 4.076 108.329 4.958
201912 4.052 108.420 4.925
202003 3.717 108.902 4.498
202006 3.741 108.767 4.532
202009 3.500 109.815 4.200
202012 3.229 109.897 3.872
202103 3.050 111.754 3.596
202106 2.919 114.631 3.356
202109 2.999 115.734 3.415
202112 2.973 117.630 3.331
202203 2.503 121.301 2.719
202206 2.542 125.017 2.679
202209 2.656 125.227 2.795
202212 2.332 125.222 2.454
202303 2.153 127.348 2.228
202306 2.236 128.729 2.289
202309 2.070 129.860 2.101
202312 2.405 129.419 2.449
202403 2.588 131.776 2.588

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


ACADIA Pharmaceuticals  (FRA:DR6) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


ACADIA Pharmaceuticals Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of ACADIA Pharmaceuticals's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


ACADIA Pharmaceuticals (FRA:DR6) Business Description

Traded in Other Exchanges
Address
12830 El Camino Real, Suite 400, San Diego, CA, USA, 92130
Acadia Pharmaceuticals Inc is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.

ACADIA Pharmaceuticals (FRA:DR6) Headlines

No Headlines